An announcement from Orthofix ( (OFIX) ) is now available.
Orthofix Medical Inc. reported a 7% increase in third-quarter 2024 net sales, reaching $196.6 million, driven by strong performance in U.S. markets, including 18% growth in Spine Fixation and 15% in Orthopedics. Despite a net loss of $27.4 million, the company achieved a significant EBITDA margin expansion and positive free cash flow. Orthofix also introduced new three-year financial targets and announced a $275 million credit facility to support long-term growth, reiterating its confidence in sustainable growth trends and shareholder value enhancement.
Find detailed analytics on OFIX stock on TipRanks’ Stock Analysis page.
